The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biotechnology Assets's Revenue for the
six
months ended in Dec. 2025 was €2.11 Mil. Biotechnology Assets's average Accounts Receivable for the
six
months ended in Dec. 2025 was €3.02 Mil.
Hence, Biotechnology Assets's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.70.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biotechnology Assets Receivables Turnover Related Terms
Biotechnology Assets Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Biotechnology Assets's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a Receivables Turnover of 0.70 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biotechnology Assets and its competitors. According to the industry distribution chart, Biotechnology Assets ranks #771 out of 839 companies in the Biotechnology industry, placing it in the top 91.9%.
Is Biotechnology Assets' Receivables Turnover too high?
Biotechnology Assets' current Receivables Turnover is 0.70. The Biotechnology industry median Receivables Turnover is 5.27. Biotechnology Assets' value of 0.70 is 86.7% below this industry median. Based on the distribution chart, Biotechnology Assets ranks #771 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biotechnology Assets has a GF Score™ of 22/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #771 out of 839 companies for Receivables Turnover. This places Biotechnology Assets in the lower half of its industry. The industry median Receivables Turnover is 5.27. Biotechnology Assets' value of 0.70 is 86.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotechnology Assets's current Receivables Turnover of 0.70 is 86.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biotechnology Assets and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotechnology Assets's current Receivables Turnover is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.22 — trading 28% below its estimated fair value. The current Receivables Turnover is 0.70 and 86.7% below the Biotechnology industry median of 5.27. Biotechnology Assets' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Receivables Turnover is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.22 is trading 28% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
Receivables Turnover: 0.70
GF Value™: €0.30 vs. price of €0.22 (28% below fair value)
Industry Position: 86.7% below the Biotechnology median (#771 of 839)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score
Get the complete analysis for XMAD:BST
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
